Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: A randomized clinical trial

JAMA

Volumn 311, Issue 17, 2014, Pages 1760-1769

  Munoz, Flor M ^a   Bond, Nanette H ^a   Maccato, Maurizio ^a,b   Pinell, Phillip ^a,b   Hammill, Hunter A ^c   Swamy, Geeta K ^d   Walter, Emmanuel B ^d   Jackson, Lisa A ^e   Englund, Janet A ^f   Edwards, Morven S ^a   Healy, C Mary ^a   Petrie, Carey R ^g   Ferreira, Jennifer ^g   Goll, Johannes B ^g   Baker, Carol J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Woman's OB GYN Specialists   (United States)

^c Private Practice   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PLACEBO;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CHILD DEVELOPMENT; CHILD GROWTH; CONTROLLED STUDY; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FEVER; GESTATIONAL AGE; HEADACHE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MYALGIA; NEWBORN TETANUS; OUTCOME ASSESSMENT; PERTUSSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLACENTAL TRANSFER; PRENATAL CARE; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; TETANUS PROPHYLAXIS; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIBODY FORMATION; CHILD DEVELOPMENT; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY TRIMESTER, THIRD; WHOOPING COUGH; YOUNG ADULT;

EID: 84899886515     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.3633     Document Type: Article

References (24)

1. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22(7):628-634.
2. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004;190(2):335-340.
3. Gonik B, Puder KS, Gonik N, Kruger M. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol. 2005;13(2):59-61.
4. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis. 1990;161(3):487-492.
5. Broder KR, Cortese MM, Iskander JK, et al Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1-34.
6. Kretsinger K, Broder KR, Cortese MM, et al Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1-37.
7. Murphy TV, Slade BA, Broder KR, et al Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Recomm Rep. 2008;57(26):723]. MMWR Recomm Rep. 2008;57(RR-4):1-51.
8. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(41):1424-1426.
9. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62(7):131-135.
10. Kapasi A, Meade BD, Plikaytis B, et al. Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays. Clin Vaccine Immunol. 2012;19(1):64-72.
11. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012-1019.
12. Centers for Disease Control and Prevention. Pertussis Surveillance Report. http://www.cdc.gov/pertussis/surv-reporting.html. Accessed June 30, 2013.
13. Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr. 2012;161(6):1091-1096.
14. Castagnini LA, Healy CM, Rench MA, Wootton SH, Munoz FM, Baker CJ. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis. 2012;54(1):78-84.
15. Halperin BA, Morris A, Mackinnon-Cameron D, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis. 2011;53(9):885-892.
16. Zheteyeva YA, Moro PL, Tepper NK, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol. 2012;207(1):e1-e7.
17. Abstracts of the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Chicago, Illinois, USA. August 14-17, 2011. Pharmacoepidemiol Drug Saf. 2011;20(suppl 1):S1-S364.
18. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol. 2011;204(4):e1-e5.
19. Taranger J, Trollfors B, Lagergård T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis. 2000;181(3):1010-1013.
20. Heininger U, Riffelmann M, Bär G, Rudin C, von König CH. The protective role of maternally derived antibodies against Bordetella pertussis in young infants. Pediatr Infect Dis J. 2013;32(6):695-698.
21. Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013;131(6):e1716-e1722.
22. Glezen WP. Effect of maternal antibodies on the infant immune response. Vaccine. 2003;21(24):3389-3392.
23. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics. 1995;96(3, pt 2):580-584.
24. Hardy-Fairbanks AJ, Pan SJ, Decker MD, et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J. 2013;32(11):1257-1260.